Cerenome, Inc. CNSY
Medical/Dental Instruments · data as of November 13, 2026
Cerenome, Inc. (CNSY) is a healthcare company listed in the US with a market value of about $7M. In the twelve months to September 30, 2026 it had revenue of $4M and net income of -$30M, a net margin of -859.5%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -218%.
About Cerenome
Cerenome is listed in the US and classified in medical/dental instruments. Revenue went from $5M in 2014 to $5M in 2025, growth of about 0.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 4345% over three years (dilution for shareholders). It spends 161% of revenue on research and development.
Score: 0.4 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $5M | $6M | $5M | — | — | — | — | $4M | $3M | $5M |
| Net income | -$30M | -$22M | -$13M | -$13M | -$20M | -$13M | -$8M | -$11M | -$13M | -$23M | -$22M |
| Free cash flow | -$29M | -$21M | -$11M | -$13M | — | — | — | -$6M | -$12M | -$18M | -$20M |
| EPS (diluted) | $-3.36 | $-2.90 | $-23.40 | $-42.40 | $-115.80 | $-166.50 | $-279.00 | $-1240.50 | $-13047.00 | $-61725.02 | $-96000.04 |
| Net margin | -859.5% | -429.4% | -222.8% | -271.0% | — | — | — | — | -344.2% | -843.7% | -473.5% |
| ROIC | — | -317.6% | — | -371.5% | -128.8% | -55.4% | -75.6% | -22.2% | -35.6% | -61.4% | -54.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $27.75, 2820% above the current price; targets range from $12.00 to $43.00; the consensus rating is “none”; expected EPS is $-4.43 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Cerenome pay a dividend?
Not currently.
Is Cerenome a good stock to buy?
We do not give buy or sell advice. Cerenome scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.